Key stats
About HUATAI-PINEBRIDGE FUND MANAGEMENT HANG SENG INNOVATIVE DRUG ETF CNY
Home page
Inception date
Dec 16, 2024
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
Huatai-PineBridge Fund Management Co., Ltd.
ISIN
CNE100006GB7
Closely track the performance of the underlying index and seek to minimize tracking deviation and tracking err.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
No, 520500 doesn't pay dividends to its holders.
520500 shares are issued by Huatai-PineBridge Fund Management Co., Ltd. under the brand Huatai. The ETF was launched on Dec 16, 2024, and its management style is Passive.
520500 expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
520500 follows the Hang Seng Innovative Drug Index yield - HKD - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
520500 price has risen by 18.32% over the last month, and its yearly performance shows a 51.79% increase. See more dynamics on 520500 price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 14.91% over the last month, showed a 20.61% increase in three-month performance and has increased by 57.82% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 14.91% over the last month, showed a 20.61% increase in three-month performance and has increased by 57.82% in a year.
520500 trades at a premium (0.50%) meaning the ETF is trading at a higher price than the calculated NAV.